Company Insights

AIMD customer relationships

Explore interactive graphBrowse insights index
AIMD customer relationship map

Ainos (AIMD) customer map: commercial traction in SmellTech and what it means for investors

Ainos monetizes a hardware-plus-subscription SmellTech stack—selling AI Nose devices and recurring software and deployment services through a mix of direct pilots and distribution partnerships. Revenue stems from multi-year deployment contracts, minimum-device purchase commitments with distributors, and subscription orders with large industrial customers, creating a path from pilot to recurring deployment revenue as the platform scales.

If you want a consolidated view of how these commercial ties translate into revenue runway and execution risk, start here: https://nullexposure.com/

Why the customer list matters: industrial scale vs. boutique pilots

Ainos has transitioned from pharma-focused pilots toward industrial rollouts across semiconductor and robotics ecosystems, shifting its monetization from one-off product sales to multi-year subscription and distribution contracts. Key commercial indicators include a $2.1 million subscription order with ASE and a three‑year distribution/deployment agreement with a minimum 600-unit commitment from Trusval—both signals of deployment-driven recurring revenue rather than standalone hardware flips.

Company-level constraints that shape the operating model

These relationship signals sit alongside company disclosures that define Ainos’ go-to-market and risk posture:

  • Distribution-first contracting posture. Ainos explicitly uses distributors and appointed Inabata as a non-exclusive worldwide distributor, signaling reliance on channel partners for market coverage.
  • Global orientation with APAC concentration. Disclosures and partner names indicate global distribution relationships but with strong APAC exposure, reflecting early industrial adoption in Taiwan and Japan.
  • Early-stage revenue recognition and working capital dynamics. The company reported contract liabilities of roughly $106k for cash received in advance from distribution channels, a signal of nascent recurring bookings and early monetization scale.
  • Mixed relationship maturity. Most relationships are active, but the company has also terminated legacy product lines (COVID antigen kits), showing a pivot from earlier revenue sources toward SmellTech.
  • Spend dispersion. Recorded small contract liabilities coexist with discrete larger orders (e.g., the ASE subscription), indicating heterogeneous customer spend as Ainos moves from pilots to larger industrial deployments.

These constraints collectively indicate a company in transition: scaling distribution and recurring contracts, concentrated by APAC industrial partners, and still early in revenue maturity.

If you want to track these commercial changes in real time, visit https://nullexposure.com/ for updated relationship signals.

Customer relationships — who Ainos is working with and why each matters

Below are the relationships reported in public disclosures and press coverage, each summarized in plain English with source context.

Trusval Technology / Trusval Technology Co. Ltd. / Trusval (FY2026)

Ainos signed a three‑year distribution and deployment agreement with Trusval, under which Trusval will act as an authorized sales agent and deployment partner for AI Nose in semiconductor front-end manufacturing and has a contractually defined minimum commitment of 600 AI Nose units to support wafer fabrication deployments (press releases and financialwire reports, Jan 2026 / FY2026).
Source: FinancialContent and TradingView press release coverage (FY2026).

ASE Technology Holding Co., Ltd. (ASEH / ASE / ASEJF) (FY2025–FY2026)

Ainos secured a three‑year subscription‑based order valued at $2.1 million with ASE, and a memorandum frames a multi‑phase expansion to integrate the AI Nose into ASE’s packaging and testing facilities with more than 30 identified use cases for predictive maintenance and environmental safety (StockTitan and company filings, FY2025–FY2026).
Source: StockTitan news items and related press coverage (FY2025–FY2026).

Mirle Automation Corporation (FY2026)

Ainos entered a technology partnership with Mirle to integrate AI Nose into Mirle’s mobile and quadruped robotic platforms, extending deployments into autonomous systems and industrial environments such as semiconductor fabs (company press release and research notes, FY2026).
Source: StockTitan and Water Tower Research coverage (FY2026).

NEXCOM International Co., Ltd. / NEXCOM (FY2025–FY2026)

Ainos and NEXCOM are co-developing and marketing integrated SmellTech and SLM solutions, with Ainos supplying hardware and software to support intelligent monitoring and predictive maintenance—an industrial alliance cited alongside IP expansion to 123 patents (StockTitan / Water Tower Research, FY2025–FY2026).
Source: StockTitan reporting and research summaries (FY2025–FY2026).

Topco Scientific Co., Ltd. / Topco Scientific (FY2025–FY2026)

Topco will distribute AI Nose hardware and software across the U.S., Taiwan, Japan, and Southeast Asia, with Ainos providing technical resources and training to push adoption in advanced markets (company financial report summary, FY2025–FY2026).
Source: StockTitan news and company commentary (FY2025–FY2026).

Solomon (FY2026)

Solomon is named among partners in large‑scale industrial SmellTech rollouts, referenced as part of a progression from pharma pilots to industrial deployments with ASE and others (research coverage, FY2026).
Source: Water Tower Research and StockTitan summaries (FY2026).

Kenmec (FY2026)

Kenmec is listed among partners in the company’s industrial SmellTech expansion as Ainos moves beyond pharma pilots, indicating channel and systems integration activity in industrial segments (research notes, FY2026).
Source: Water Tower Research coverage (FY2026).

Taiwan Tanabe Seiyaku (FY2026)

Collaborations with Taiwan Tanabe Seiyaku centered on the VELDONA product line and related pharma applications in Dec 2024, marking earlier clinical or therapeutics-focused commercial activity prior to the industrial push (research notes, FY2026 referencing Dec 2024 activity).
Source: Water Tower Research (FY2026; references Dec 2024).

ugo (UGODF) (FY2025)

Ainos completed the first installation of AI Nose on ugo’s service robots and integrated backend control systems, demonstrating early robotics use cases and software interoperability (research coverage, FY2025).
Source: Water Tower Research / StockTitan coverage (FY2025).

Commercial implications for investors and operators

  • Scaling model: Ainos is executing a classic channel + anchor-customer approach—distributors provide breadth while large OEMs like ASE provide depth and recurring subscription revenue. The Trusval 600‑unit minimum and ASE $2.1M order are concrete examples of this hybrid model.
  • Concentration and geography: APAC industrial partners dominate early traction, which accelerates semiconductor use cases but concentrates geopolitical and customer-concentration risk.
  • Revenue runway and maturity: Contract liabilities in the low six figures show bookings that are real but early, while discrete multi-million dollar subscription orders indicate an ability to close larger industrial contracts as pilots convert.
  • Execution risks: The company still relies on channel partners and variable pilot-to-deployment conversion; termination of legacy COVID product lines demonstrates a willingness to pivot revenue sources aggressively.

If you want ongoing tracking and a single-pane view of these evolving customer ties, visit https://nullexposure.com/ for the latest signals and relationship roll-ups.

Bottom line

Ainos’ commercial evidence shows a shift from pilot-stage, pharma-oriented trials to industrial-scale, subscription-driven deployments anchored by distribution agreements and strategic OEM partners. For investors and operators, the critical metrics to watch are deployment cadence (units shipped under distribution deals), subscription ARR from anchor customers like ASE, and geographic concentration risk as APAC remains the primary growth corridor.

For a live feed of these customer relationships and to integrate them into investment workflows, go to https://nullexposure.com/ and subscribe for alerts and consolidated reports.